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Abstract
Objectives: This study explored the expression and function of Slug in human extrahepatic hilar cholangiocarcinoma
(EHC) to identify its role in tumor progression.
Methods: The expression of Snail and Slug mRNA in 52 human tissue samples of EHC was investigated. The mRNA
of Snail and Slug were quantified using reverse transcriptase-PCR, and correlations with E-cadherin expression and
clinicopathological factors were investigated. We then investigated transfection of Slug cDNA in endogenous
E-cadherin-positive human EHC FRH0201 cells, selectively induced the loss of E-cadherin protein expression, and
then small interfering RNA (siRNA) for inhibition of Slug expression in endogenous Slug-positive human EHC
QBC939 cells, selectively induced the loss of Slug protein expression. A Boyden chamber transwell assay was used
for invasion.
Results: Slug mRNA was overexpressed in 18 cases (34.6%) of EHC compared with adjacent noncancerous tissue.
E-Cadherin protein expression determined in the same 52 cases by immunohistochemistry was significantly down-
regulated in those cases with Slug mRNA overexpression (P = 0.0001). The tumor and nontumor ratio of Slug
mRNA was correlated with nodal metastasis(p = 0.0102), distant metastasis (p = 0.0001)and Survival time(p =
0.0443). However, Snail mRNA correlated with neither E-cadherin expression nor tumor invasiveness. By inhibiting
Slug expression by RNA interference, we found that reduced Slug levels upregulated E-cadherin and decreased
invasion in QBC939 cell. When the QBC939 cells was infected with Slug cDNA, significant E-cadherin was
downregulated and increased invasion in QBC939 cell.
Conclusions: The results suggested that Slug expression plays an important role in both the regulation of
E-cadherin expression and in the acquisition of invasive potential in human EHC. Slug is possibly a potential target
for an antitumor therapy blocking the functions of invasion and metastasis in human EHCs.
Introduction
Cholangiocarcinoma is a cancer arising from bile duct
epithelium. It is one of the most difficult diseases to
treat. Three-year survival rates of 35 to 50% can be
achieved in only a few numbers of patients when nega-
tive histological margins are attained at the time of sur-
gery [1]. The reason for this poor prognosis is that
cholangiocarcinoma exhibits extensive local invasion
and frequent regional lymph node metastasis[2]. but the
mechanisms through which Cholangiocarcinoma
acquires such invasive potentials are not well
understood.
E-Cadherin-mediated cell-to-cell adhesion plays a
critical role in the maintenance of cell polarity and
environment [3]. E-Cadherin was reported to be down-
regulated and closely related to tumor invasion and
metastasis in many cancers[4-6] . Genetic and epige-
netic alteration of E-cadherin was also reported [3] .
Somatic mutation, loss of heterozygosity of the E-cad-
herin gene, and CpG methylation around the promoter
region of the E-cadherin gene were noted in human
gastric cancer, breast cancer, and Hepatocarcinoma
[7-11]. However, E-cadherin promoter hypermethyla-
tion is not always associated with loss of expression
[11], and evidence has been presented that E-cadherin
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than promoter hypermethylation [8] . The heterogene-
ity and reversibility of E-cadherin protein expression
are both controversial areas [3]. Recently, the Slug
transcription factor was reported to directly repress
E-cadherin expression in many epithelial cancers asso-
ciated with epithelial-mesenchymal transitions [12].
Reverse correlation of Slug and E-cadherin expression
has been noted in many malignant cells[13-19]. It has
reported that Snail, a zing-finger protein, is a likely
repressor of E-cadherin in carcinoma Cells[20-22].
However, we can find no documentation regarding the
expression of Snail or Slug in human EHC tissue. In
this study, we investigated whether Slug represses
E-cadherin expression in human EHC cells. The levels
of expression a of Snail and Slug mRNA were detected
in a series of human EHC samples, and correlations
between Snail/Slug expression and clinicopathological
factors were analyzed. Our evidence suggests that Slug,
rather than Snail, may contribute to both E-cadherin
expression and to the progression of EHCs.
Materials and methods
Patients
This present retrospective study was based on data
obtained using surgically resected tissues from 52 conse-
cutive Chinese patients who underwent hepatectomy for
EHCs. Written informed consent was obtained from
each patient before tissue acquisition. All data were col-
lected in the Department of Anatomical Pathology, Affl-
ited hospital of Qingdao medical college, Qingdao
university (Qingdao, China) from July 2000 to Sep.
2008. All tumors were defined as EHC, and pathological
features of the tumors were determined histologically
based on classifications oft h eL i v e rC a n c e rS t u d y
Group of China . Histological grades of the tumors con-
sisting of more than two features were defined by the
most prominent feature, and those components were
selected for immunohistochemical studies.
Real-Time Quantitative RT-PCR of Snail and Slug
Total RNA was extracted and purified from 52 paired
samples of fresh frozen cancerous tissues and noncan-
cerous bile tissues using Trizol Reagent (Life Technolo-
gies, Inc.) according to the manufacturer’si n s t r u c t i o n s .
For reverse transcriptase reaction, we used 5 μgo ft h e
RNA, random hexamers, and Superscript II reverse tran-
scriptase (Life Technologies, Inc.) according to the man-
ufacturer’s instructions. The oligonucleotide primers
and TaqMan probes designed for Snail and Slug were as
follows: Snail (5′-ACCACTATGCCGCGCTCTT-3′ and
5′-GGTCGTAGGGCTGCTGGAA-3′); Slug (5′-TGTT
GCAGTGAGGGCAAGAA-3′ and 5′-GACCCTGGTTG
CTTCAAGGA3′); and TaqMan probe (Snail, 5′-6FAM-
TCGTCAGGAAGCCCTCCGACCC-TAMRA-3′ and
Slug, 5′-6FAM-AGGCTTCTCCCCCGTGTGAGTTC-
TAATG-TAMRA-3′). Each primer was placed in a dif-
ferent exon to avoid amplification of contaminating
genomic DNA. Primers and probe for GAPDH (Taq-
Man GAPDH control reagent kit) were purchased from
Perkin-Elmer Applied Biosystems (Foster City, CA).
R e a l - t i m eq u a n t i t a t i v eP C Rw a sd o n eu s i n gt h eA B I
Prism 7700 Sequence Detection System (Perkin-Elmer
Applied Biosystems), as described above. Real-time PCR
assays were done in triplicate, and the mean values were
used for calculations of mRNA expression. Finally, the
Snail and Slug mRNA expression ratios for tumorous
(T) and nontumorous (N) tissues were calculated as fol-
lows: R = [Snail or Slug (T)/GAPDH (T)]/[Snail or Slug
(N)/GAPDH (N)] × 102. Cases were designated as either
overexpression (R > 100) or nonoverexpression (R ≤
100) cases.
Immunohistochemical Staining of E-Cadherin
Formalin-fixed, paraffin-embedded tissue sections from
52 EHC cases that corresponded to the RNA extracted
cases were processed for immunohistochemical staining,
as described previously [23]. A primary monoclonal Ab
against E-cadherin (diluted 1:1000; Transduction
Laboratories) was used. Positive immunoreactivity of
normal bile duct epithelium was confirmed as a positive
control for each specimen [24]. Immunohistochemical
staining was examined under a light microscope by two
pathologists. The cell staining of E-cadherin was evalu-
ated semiquantitatively, and tumors were divided into
two groups: (a) preserved pattern: >75% of tumor cells
staining and (b) reduced pattern: <75% of tumor cells
staining, as described elsewhere [23] .
Real-time RT-PCR for E-cadherin mRNA and Slug mRNA in
EHC cell lines
QBC939, SK-Ch-1, FRH 0201 cells, the cultured
human EHC cell line, were supplied from Cell
Resource Center, FUDAN University (Shanghai,
China). These cells were cultured at 37°C in 5% CO2
in RPMI 1640, containing 10% FBS. Upon reaching
70% confluence cells were lysed into Trizol reagent
(Gibco, UK) for mRNA extraction and evaluation of
E-cadherin mRNA and Slug mRNA expression by
Real-time quantitative RT-PCR. Real-time quantitative
PCR was done using the ABI Prism 7700 Sequence
Detection System (Perkin-Elmer Applied Biosystems)
as described previously [23]. Briefly, each PCR mixture
contained 1 μlo fc D N A ,T a q M a nU n i v e r s a lP C Rm a s -
ter mix (Perkin-Elmer Applied Biosystems), primer
pair, and TaqMan probe in a final volume of 50 μl.
The PCR conditions were an initial denaturation step
of 2 min at 50°C and 10 min at 95°C, followed by 40
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Serial 1:10 dilutions of plasmid DNA were analyzed for
each target cDNA, and these served as standard curves
from which we determined the rate of change of
threshold cycle values. The amount of target gene
expression was calculated from the standard curve, and
quantitative normalization of Slug cDNA in each sam-
ple was done using GAPDH as an internal control.
Subcloning of Human Slug cDNA and Construction of
Expression Plasmids
The full coding region of human Slug was amplified by
PCR using primers (5′-GCTGTAGGAACCGCCGT
GTC-3′ and 5′-ATTTGTCATTTGGCTTCGGAGTG-3′)
from cDNA of human EHC, and the product was cloned
into the pT7 Blue vector (Novagen, Madison, WI). Iso-
lated DNA sequences were determined using a cycle
sequencing procedure. Slug cDNA was then subcloned
into the bicistronic expression vector pGEM-T -EGFP
(Clontech, Palo Alto, CA), which allows for translation
of both the genes of interest and the EGFP.
Cell Culture and Transient Transfection of Slug cDNA
FRH 0201 cells were cultured at 37°C in 5% CO2 in
RPMI 1640 (Life Technologies, Inc., Rockville, MD),
containing 10% FBS (Life Technologies, Inc.). FRH 0201
cells (1 × 106) were grown in 3.5-cm dishes and transi-
ently transfected with 2 μg of the pSlug-EGFP plasmid,
as well as the empty pEGFP (mock) plasmid using Lipo-
fectamine (Life Technologies, Inc.), according to the
manufacturer’s instructions. At 48 h after transient
transfection, Slug siRNA-transfected cells, which
expressed both Slug and EGFP, were confirmed by epi-
luminescence fluorescence microscopy (Axioscop2,
Zeiss, Germany) .
Small interfering RNA (siRNA) for inhibition of slug
expression
Three stealth small interfering RNA (siRNA) duplex
oligoribonucleotides specific for Slug were synthesized.
The sequences were as follows:
1) sense 5′-UUAACAGCAAACUCAGUUGAAAU
GG-3′,
antisense 5′-CCAUUUCAACUGAGUUUGCUGUU
AA-3′;
2) sense 5′-UGAAUUAGGAAACUGAUCUUCC
GGA-3′,
antisense 5′-UCCAGAAGAUC AGUUUCCU AAU
UCA-3′;
3) sense 5′-AAAUCUUUCAUGAUGAUUCCCU
CGG-3′,
antisense 5′- CCGAGGGAAUCAUGAAAGAUU U-3′.
siRNA oligos were transfected into cholangiocarcinoma
cells by using BLOCK-iT transfection kit (Invitrogen,
Carlsbad, CA) according to the manufacturer’sp r o t o c o l .
The BLOCK-iT fluorescent oligo that is not homologous
to any known genes was used as transfection efficiency
detector and a negative control to ensure against induc-
tion of non-specific cellular events caused by introduc-
tion of the oligo into cells. Among the three siRNA oligo
duplexes specific for slug, the one that required the smal-
lest concentration to achieve the desired knockdown
effect was selected and used in all experiments.
Real-time RT-PCR for E-cadherin mRNA after transient
transfection of Slug siRNA
siRNA oligos were transfected into QBC939 (the highest
level of Slug expression) cells (2 × 105) by using
BLOCK-iT transfection kit (Invitrogen, Carlsbad, CA)
according to the manufacturer’sp r o t o c o lf o r4 8h .T h e
mRNA inhibiting levels were assayed with Real-time
RT-PCR .
Tumor invasion in Matrigel-coated chambers
To determine invasive ability, siRNA-Slug , Slug cDNA
or mock control cells (1.25 × 105 per well)were plated
on the BD Matrigel invasion chambers (BD Biosciences).
Medium in the upper chamber was supplemented with
5% FCS. In the lower chamber, FCS concentration was
10%. After 24 h, cells migrated into the lower chamber
were stained and counted. Experiments were carried out
in triplicate and repeated twice.
Statistical Analysis
Follow-up was obtained through office records, tele-
phone contact, or E-mail. Patient follow-up was com-
plete up to September, 2008. Survival was calculated
from the date of resection to one year after postopera-
tion. All results were expressed as mean ± SE. Compari-
sons between Snail/Slug expression levels (R; > 100 or ≤
100) and E-cadherin expression patterns were evaluated
using c
2 test, and comparisons between the Snail/Slug
expression ratios and clinicopathological parameters
were evaluated using t test or F test. P of < 0.05 was
considered to have statistical significance.
Results
Expression of Slug and Snail mRNA in extrahepatic hilar
cholangiocarcinoma
We quantified the copy numbers of Slug and Snail
mRNA in 52 pairs of EHC tissue and noncancerous bile
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Sequence Detection System, as described above. The
copy number of Slug, Snail and GAPDH mRNA ranged
from 218.4 to 83096, 117.8 to 15262, and 1238.56 to
6287429, respectively. Slug and Snail expression were
standardized using the expression of the GAPDH house-
keeping gene as the internal control. The cancerous (T)/
noncancerous (N) ratio of mRNA (R) was then calcu-
lated to determine Snail and Slug mRNA levels in each
case. Slug mRNA levels in cancerous tissue ranged from
0.823 to 58.9 (mean ± SE: 13.8 ± 3.1) and that of non-
cancerous tissue from 4.14 to 142 (mean ± SE: 39.6 ±
4.8). The ratio (R) of Slug ranged from 0.04 to 658
(mean ± SE: 63.4 ± 19.3). 18 (34.6%) of 52 examined
samples were defined as cases overexpressing Slug
mRNA. The Snail mRNA levels were from 2.18 to 342
(mean ± SE: 47.8 ± 13.02) in cancerous tissue and from
8.80 to 163 (mean ± SE: 62.45 ± 6.8) in noncancerous
tissue. The ratios (R) of Slug ranged from 3.14 to 1049
(mean ± SE: 132 ± 38.6). 12 (23%) of 52 samples exam-
ined were defined as cases overexpressing Snail mRNA.
Relationship between Slug and Snail expression and
clinicopathologic data
The relationship between Slug and Snail expression and
clinicopathologic features is summarized in Table 1. The
mean Slug mRNA ratio was significantly higher in cases
of nodal metastasis (59.8 versus 77.4, P = 0.0102)and
distant metastasis (64.8 versus 146.3, P = 0.0001).
Patients with increased Slug mRNA(9/52)survived signif-
icantly shorter than those with reduced Slug mRNA
expression (43/52) (P = 0.0443). Cases of lymphatic
invasion and perineural invasion also had high Slug
mRNA ratios compared with the cases without invasion,
although there was no statistical significance because of
the distribution of the ratio [76.5 versus 68.3 (P =
0.1404), 60.4 versus 54.9 (P = 0.134), respectively. There
was no statistical significance of Snail expression on
clinicopathological parameters.
Among the 18 Slug overexpression cases, 13 cases
(72.2%) showed portal veini n v a s i o na n d7( 3 8 . 9 % )
showed liver artery invasion, whereas there were only 7
(20.6%)with portal vein invasion and 2 (5.9%) with liver
artery invasion in 34 cases of Slug nonoverexpression.
In addition, 10/18 showed remarkably high Slug
mRNA levels (R >2 0 0 ) ,a n dt h e s ew e r ea l lw i t hp o r t a l
vein invasion.
E-cadherin protein expression in EHC samples with or
without Snail/Slug mRNA overexpression
Expression of E-cadherin protein was also analyzed
immunohistochemically. E-cadherin was expressed in
membrane and/or cytoplasm.19 of 52 EHCs (36.5%) had
a reduced expression pattern (Fig. 1). These findings did
not significantly correlate with clinicopathological fea-
tures such as distant metastasis, portal vein invasion,
and liver artery invasion. The relationship between
Snail/Slug mRNA expression and E-cadherin protein
expression patterns was then determined in the EHC
samples. Slug mRNA overexpression significantly corre-
lated with E-cadherin reduced expression (Table 2) . 13
(72.2%) of 18 cases overexpressing Slug showed a
reduced E-cadherin expression pattern, whereas only 6
of 34 cases of Slug nonoverexpression (17.6%) had a
reduced pattern, with a statistically significant difference
(P = 0.0001). However, there was no significant correla-
tion between Snail overexpression and E-cadherin
expression (Table 2).
Ectopic expression of Slug to down-regulate E-Cadherin
expression in EHC cell lines
E-Cadherin mRNA expression was examined in a panel
of three cholangiocarcinoma cell lines QBC939, SK-Ch-
1, FRH 0201 by real-time PCR and results showed that
the cell line FRH 0201 had the highest expression level
of E-Cadherin mRNA and the lowest expression of Slug
mRNA (Fig 2A). In this regard, the cell line FRH 0201
was chosen for the studies..
T h ec e l ll i n eF R H0 2 0 1w a st ransiently transfected
with either full length human Slug cDNA-GFP vector or
the control empty GFP vector. 48 h after transfection,
cells were lysed and processed for mRNA analysis. In
Fig 2B, the green fluorescent color indicates FRH 0201
cells transfected with control empty GFP vector. Cells
were counted on the photographs and the ratio between
green fluorescent cells and total cell number was taken
as transfection efficiency. The transfection efficiency was
43.6% 48 h after transfection.
Slug transfectants showed a remarkably reduced
expression of E-cadherin protein, whereas positive E-
cadherin expression was observed in nontransfected
FRH 0201 cells. On the other hand, E-cadherin expres-
sion was homogeneously preserved in mock-transfected
cells (Fig 2C). These observations provided direct
evidence that Slug repressed E-cadherin expression in
human cholangiocarcinoma cells.
siRNA Slug increases E-cadherin expression
Slug mRNA expression was examined in a panel of
three cholangiocarcinoma cell lines QBC939, SK-Ch-1,
FRH 0201 by real-time PCR and results showed that the
cell line QBC939 had the highest expression level of
Slug mRNA (Fig 3A). In this regard, the cell line
QBC939 was chosen for the studies. The cell line
QBC939 was transiently transfected with Slug siRNA
oligos for 48 h by using BLOCK-iT transfection kit.
Cells were lysed and processed for mRNA analysis. The
transfection efficiency was 32.4% 48 h after transfection
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increased expression of E-cadherin. (Fig 3A). The obser-
vations provided direct evidence that Slug inhibition
increased E-cadherin expression in human cholangio-
carcinoma cells.
Cell invasion detection
We tested whether Slug knockdown affected the inva-
sion capabilities of QBC939 cells by using an in vitro
invasion assay. Cells were seeded in the upper part of a
Matrigel-coated invasion chamber in a reduced (5%)
FCS concentration. After 24 h, cells that migrated in the
lower chamber containing a higher (10%) FCS concen-
tration were stained and counted. In Slug-silenced cell
lines, invasion was significantly reduced (Fig. 4A; P <
0.05). Compared with untreated cells, or mock-siRNA
cells, no further decrease in invasion was observed .
We also tested the effects of Slug overexpression on
the invasion capability of FRH 0201 cells. Compared
with data obtained using the parental cell lines, Slug
Table 1 Comparison of clinicopathological variables dependent on Snail and Slug mRNA ratios
Slug mRNA (mean ± SE) P Snail mRNA (mean ± SE) P
mean age (yr)
<65(15) 86.9 ± 25.5 149.3 ± 57.4
>65(37) 78.3 ± 19.7 0.1969 171.2 ± 62.8 0.249
Gender
62.2 ± 32.3 62.2 ± 32.3 127.4 ± 35.6
70.6 ± 17.5 70.6 ± 17.5 0.2415 124.3 ± 71.8 0.8488
Histologic grading
G1 (29) 66.4 ± 13.6 107.2 ± 60.2
G2 (16) 58.0 ± 26.56 114.7 ± 53.5
G3 (7) 73.2 ± 33.8 0.2523 125.4 ± 41.4 0.7252
Histology
Well(13) 69.2 ± 18.4 95.7 ± 28.3
Mod.(27) 76.0 ± 15.8 108.4 ± 46.5
Poor(12) 85.6 ± 29.2 0.135 100.7 ± 31.1 0.6109
Depth of invasion
T1(8) 79.2 ± 12.4 117.1 ± 28.0
T2(32) 68.4 ± 19.7 98.4 ± 34.6
T3(12) 80.2 ± 30.5 0.1962 109 ± 36.3 0.3260
Surgical margin involvement
Negative (n = 38) 66.4 ± 16.7 102.6 ± 49.4
Positive (n = 14) 77.6 ± 31.5 0.2277 124.8 ± 60.0 0.197
Nodal metastasis
Negative (n = 32) 59.8 ± 23.3 86.8 ± 75.6
Positive (n = 20) 77.4 ± 22.8 0.0102 109.8 ± 35.2 0.1448
Lymphatic invasion
Negative (n = 10) 68.3 ± 10.9 180.3 ± 49.4
Positive (n = 42) 75.6 ± 16.4 0.1404 154. 5 ± 40.1 0.0865
Venous invasion
Negative (n = 15) 79.6 ± 30.7 120 ± 121.7
Positive (n = 37) 87.2 ± 24.6 0.3524 134.5 ± 30.6 0.1015
Perineural invasion
Negative (n = 12) 60.4 ± 16.8 155.2 ± 26.2
Positive (n = 40) 52.9 ± 14.4 0.134 166.3 ± 40.4 0.3758
Distant metastasis
Negative (n = 44) 64.8 ± 19.6 163.8 ± 13.6
Positive (n = 8) 146.3 ± 33.2 0.0001 143.3 ± 27.5 0.0747
Survival (mo)
<12 (n = 9) 126.8 ± 24.5 176.5 ± 87.2
>12 (n = 43) 103.3 ± 36.7 0.0443 163.4 ± 54.4 0.5596
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sion (Fig. 4B; P < 0.05). Together, these data show that
Slug modulates invasion of EHC cells in vitro.
Discussion
Recent direct evidence shows that Snail transcription
factor and its family protein Slug repress E-cadherin
expression in human cancer cell lines[13,22,25-30].
Down-regulation of E-cadherin causes loss of cell-to-cell
adhesion. Impaired adhesion characterizes the potential
of invasion and metastases, crucial steps for progression
of hepatocarcinoma[3]. Thus, the down-regulation of E-
cadherin promotes invasion and metastases of hepato-
carcinoma and vice versa [31] . To confirm the function
of Slug in EHC, we used E-cadherin-positive FRH0201
cells and slug positive QBC939 cells reported above that
E-cadherin and Slug inversely express in FRH0201 and
QBC939 cell lines.
Our data revealed direct evidence that transient Slug
expression can suppress E-cadherin protein expression
and increased the motility and invision potential in
QBC939 cells. Transient Slug inhibition can increase
E-cadherin protein expression in FRH0201 cells, and
decreased the motility and invision potential.
We investigated Slug mRNA using RT-PCR and con-
firmed that Slug mRNA is expressed in EHC samples.
We then quantitatively analyzed the mRNA expression
levels of Slug in both cancerous and noncancerous tis-
sues of EHCs. We used the cancerous/noncancerous
ratio of Slug mRNA to evaluate Slug expression levels in
each case. 18 (34.6%) were determined to be Slug over-
expression cases, and this overexpression significantly
correlated with reduced E-cadherin expression. Our data
show that Slug, rather than Snail, functions as a sup-
presser of E-cadherin in human EHC tissue, as well as
in cultured EHC cells. Recently, Paras et al.[ 1 8 ]
reported that Slug contributed to the down-regulation
of E-cadherin expression in esophageal adenocarcinoma
lines. Although both proteins are produced in all verte-
brate species, their functions are different among various
species and different cells [32,33]. These data suggest
that E-cadherin production of carcinoma cells should be
regulated by the different transcriptional repressors
among the different cells or tissues.
Figure 1 Representative example of the E-cadherin expression determined by immunohistochemistry. A, carcinoma cells showed strong
expression (preserved pattern) in the Slug nonoverexpression case. B, carcinoma cells showed weak expression (reduced pattern) in the Slug
overexpression case. (magnification, ×400).
Table 2 Comparison of Snail and Slug expression between preserved and reduced patterns of E-cadherin
E-cadherin expression Preserved (n = 33) E-cadherin expression Reduced (n = 19) P
Slug mRNA
Overexpression (n = 18) 5 (27.8) 13 (72.2)
Nonoverexpression (n = 34) 28 (82.4) 6 (17.6) 0.0001
Snail mRNA
Overexpression (n = 12) 7 (58.3) 5(41.7)
Nonoverexpression (n = 40) 26 (65) 14(35) 0.9993
Zhang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:88
http://www.jeccr.com/content/29/1/88
Page 6 of 10Figure 2 A Expression of E-Cadher mRNA in QBC939, SK-Ch-1, FRH 0201 cells. In vitro cleavage effect of different ribozymes on E-Cadherin
mRNA and Slug mRNA. The reaction product of in vitro ribozyme cleavage was analyzed by absolute real-time quantitative PCR. The
amplification plots and standard curve were obtained with the in vitro transcript from E-Cadherin. Serial 10-fold dilutions with 9 × 108 to 9 × 10-
2 pg per reaction well were made in EASY Dilution (Takara). Amplification was repeated three times for each dilution. It showed the cell line
FRH 0201 had the highest expression of E-Cadherin m RNA and the lowest expression of Slug mRNA. B Evaluation of transfection efficiencies. It
showed the transfection efficiency was 43.6% 48 h after Slug transfection. C E-cadherin in Slug transfected and mock-transfected FRH 0201 cells.
In vitro cleavage effect of different ribozymes on E-Cadherin mRNA. The reaction product of in vitro ribozyme cleavage was analyzed by
absolute real-time quantitative PCR. The amplification plots and standard curve were obtained with the in vitro transcript from E-Cadherin. Serial
10-fold dilutions with 9 × 108 to 9 × 10-2 pg per reaction well were made in EASY Dilution (Takara). Amplification was repeated three times for
each dilution. It showed Slug overexpression repressed E-cadherin expression in FRH 0201.
Figure 3 A Expression of E-cadherin in QBC939 cells. The reaction product of in vitro ribozyme cleavage was analyzed by absolute real-time
quantitative PCR. The amplification plots and standard curve were obtained with the in vitro transcript from E-Cadherin. Serial 10-fold dilutions
with 9 × 108 to 9 × 10-2 pg per reaction well were made in EASY Dilution (Takara). Amplification was repeated three times for each dilution. It
showed Slug inhibition increased E-cadherin expression in QBC939 cells. B Evaluation of transfection efficiencies. It showed the transfection
efficiency was 31.4% 48 h after siRNA-Slug transfection.
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overexpression cases, however, there were 28 (82.4%)
with reduced E-cadherin expression but without Slug
overexpression. Kanai et al.[34] reported that 48% show
DNA hypermethylation of the E-cadherin promoter
region and 42% show loss of heterozygosity at the locus
adjacent to the E-cadherin gene in HCC. Genetic muta-
tion of the E-cadherin gene was detected in breast, gas-
tric, and gynecological cancers, which showed a uniform
loss of E-cadherin expression[35-37] . To date, a genetic
mutation of the E-cadherin gene has not been reported
in cases of EHC in which loss of E-cadherin expression
is considered to be heterogeneous and reversible. There-
fore, E-cadherin expression in EHC may be regulated
not just by the Slug transcriptional factor but also by
other genetic and/or epigenetic alterations such as DNA
mutation and/or methylation. Additional studies are
required to reveal the entire regulatory mechanism of E-
cadherin expression in EHC tumors.
In this study, Slug mRNA overexpression correlated
with metabasis and invasion of surgically resected
human EHC. High expression of Slug mRNA has signifi-
cantly shorter survival, the expression of Slug mRNA in
EHC is an independent poor prognostic factor. EHC is
hence a useful marker for predicting the outcome of
patients with EHC who had a surgical resection of the
tumor. Our data show that Slug, rather than Snail, nega-
tively regulates E-cadherin expression, but it may also
regulate the expression of other genes involved in the
invasive potential of EHC. E-Cadherin has been reported
to involve in tumor invasiveness [38-42] , but the rela-
tionships between E-cadherin and clinicopathological
factors were not consistent among these studies. In this
study, E-cadherin was not found to be related to any
clinicopathological factors. Differences of etiology and
methods of evaluation might cause this discrepancy
[40-42] . Additionally, the reversibility of E-cadherin
expression should be considered. Slug and other family
proteins bind to specific target genes and function as
transcriptional repressors, but it is considered that the
repression of E-cadherin alone is not sufficient to
explain the role of Slug in cell migration and cancer
development. The possible involvement of rhoA, rhoB,
and other molecules, as well as E-cadherin, in the Slug
pathway that controls cell motility has been considered
for Drosophila, Caenorhabditis elegans, and vertebrate
[43-46]. Additional investigations are needed to fully
understand the functions and target genes of Slug
protein in EHCs.
Acknowledgements
We take this opportunity to specifically thank the reviewers and editors for
their kind instructions that may be helpful for our further studies.
Author details
1General Surgery, the Affiliated Hospital of medical College, Qingdao
University, Qing dao, Shandong Province. 266003. China.
2Laboratorian, the
Affiliated Hospital of medical College, Qingdao University, Qing dao,
Shandong Province. 266003. China.
3Urinary surgery, the Affiliated Hospital of
medical College, Qingdao University, Qing dao, Shandong Province. 266003.
China.
4Anatomic Pathology, the Affiliated Hospital of Hainan Medical
college, Haikou. 527010. China.
Authors’ contributions
ZKJ, WDS and ZSY designed the experiments. ZKJ and JXL carried out most
of experiments and drafted the manuscript. WXS, YQC and CHN carried out
the immunohischemistry and RT-PCR. LCW and WDS participated in
statistical analysis and and interpretation of data. All authors read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 25 February 2010 Accepted: 1 July 2010
Published: 1 July 2010
Figure 4 siRNA knockdown of Slug and overexpression of Slug with the invasive potential in EHC cells. Cells were seeded in the upper
chamber in medium supplemented with 5% FCS. Results are reported as percent migration ± SD compared with untreated cells. Experiments
were carried out twice in triplicate. A Slug silencing inhibits invasion potention of QBC939 cells in Matrigel-coated invasion chambers. B Slug
overexpression promotes invasive potential in FRH 0201 cells in Matrigel-coated invasion chambers.
Zhang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:88
http://www.jeccr.com/content/29/1/88
Page 8 of 10References
1. Chamberlain RS, Blumgart LH: Hilar cholangiocarcinoma: A review and
commentary. Ann Surg Oncol 2000, 7:55.
2. Washburn WK, Lewis WD, Jenkins RL: Aggressive surgical resection for
cholangiocarcinoma. Arch Surg 1995, 130:270.
3. Hirohashi S: Inactivation of the E-cadherin-mediated cell adhesion
system in human cancers. Am J Pathol 1998, 153:333-339.
4. Mărgineanu E, Cotrutz CE, Cotrutz C: Correlation between E-cadherin
abnormal expressions in different types of cancer and the process of
metastasis. Rev Med Chir Soc Med Nat Iasi 2008, 112(2):432-6.
5. Guarino M: Epithelial-mesenchymal transition and tumour invasion. Int J
Biochem Cell Biol 2007, , 12: 2153-60.
6. Alves CC, Carneiro F, Hoefler H, Becker KF: Role of the epithelial-
mesenchymal transition regulator Slug in primary human cancers. Front
Biosci 2009, 14:3035-50.
7. Berx G, Becker KF, Hofler H, van Roy F: Mutations of the human
E-cadherin (CDH1) gene. Hum Mutat 1998, 12:226-237.
8. Cheng CW, Wu PE, Yu JC, Huang CS, Yue CT, Wu CW, Shen CY:
Mechanisms of inactivation of E-cadherin in breast carcinoma:
modification of the two-hit hypothesis of tumor suppressor gene.
Oncogene 2001, 20:3814-3823.
9. Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S:
Silencing of the E-cadherin invasion-suppressor gene by CpG
methylation in human carcinomas. Proc Natl Acad Sci USA 1995,
9:7416-7419.
10. Kanai Y, Ushijima S, Hui AM, Ochiai A, Tsuda H, Sakamoto M, Hirohashi S:
The E-cadherin gene is silenced by CpG methylation in human
hepatocellular carcinomas. Int J Cancer 1997, 71:355-359.
11. Tamura G, Yin J, Wang S, Fleisher AS, Zou T, Abraham JM, Kong D,
Smolinski KN, Wilson KT, James SP, Silverberg SG, Nishizuka S, Terashima M,
Motoyama T, Meltzer SJ: E-Cadherin gene promoter hypermethylation in
primary human gastric carcinomas. J Natl Cancer Inst (Bethesda) 2000,
92:569-573.
12. Alves CC, Carneiro F, Hoefler H, Becker KF: Role of the epithelial-
mesenchymal transition regulator Slug in primary human cancers. Front
Biosci 2009, 14:3035-50.
13. Hajra KM, Chen DY, Fearon ER: The SLUG zinc-finger protein represses
E-cadherin in breast cancer. Cancer Res 2002, 62:1613-8.
14. Rees JR, Onwuegbusi BA, Save VE, Alderson D, Fitzgerald RC: In vivo and in
vitro evidence for transforming growth factor-beta1-mediated epithelial
to mesenchymal transition in esophageal adenocarcinoma. Cancer Res
2006, 66(19):9583-90.
15. Kurrey NK, K A, Bapat SA: Snail and Slug are major determinants of
ovarian cancer invasiveness at the transcription level. Gynecol Oncol
2005, 97:155-165.
16. Uchikado Y, Natsugoe S, Okumura H, Setoyama T, Matsumoto M,
Ishigami S, Aikou T: Slug Expression in the E-cadherin preserved tumors
is related to prognosis in patients with esophageal squamous cell
carcinoma. Clin Cancer Res 2005, 11:1174-80.
17. Shioiri M, Shida T, Koda K: Slug expression is an independent prognostic
parameter for poor survival in colorectal carcinoma patients. British
Journal of Cancer 2006, 94:1816.
18. Jethwa Paras, Naqvi Mushal, Robert GHardy, Neil AHotchin, Roberts Sally,
Spychal Robert, Chris Tselepis: Overexpression of Slug is associated with
malignant progression of esophageal adenocarcinoma. World J
Gastroenterol 2008, 14:1044-1052.
19. Prasad CP, Rath G, Mathur S, Bhatnagar D, Parshad R, Ralhan R: Expression
analysis of E-cadherin, Slug and GSK3beta in invasive ductal carcinoma
of breast. BMC Cancer 2009, 9:325.
20. von Burstin J, Eser S, Paul MC, Seidler B, Brandl M, Messer M, von Werder A,
Schmidt A, Mages J, Pagel P, Schnieke A, Schmid RM, Schneider G, Saur D:
E-cadherin regulates metastasis of pancreatic cancer in vivo and is
suppressed by a SNAIL/HDAC1/HDAC2 repressor complex.
Gastroenterology 2009, 137:361-71.
21. Jin H, Yu Y, Zhang T, Zhou X, Zhou J, Jia L, Wu Y, Zhou BP, Feng Y: Snail is
critical for tumor growth and metastasis of ovarian carcinoma. Int J
Cancer 2009, 126(9):2102-2111.
22. Lopez D, Niu G, Huber P, Carter WB: Tumor-induced upregulation of
Twist, Snail, and Slug represses the activity of the human VE-cadherin
promoter. Arch Biochem Biophys 2009, 482:77-82.
23. Miyajima K, Tamiya S, Oda Y, Adachi T, Konomoto T, Toyoshiba H,
Masuda K, Tsuneyoshi M: Relative quantitation of p53 and MDM2 gene
expression in leiomyosarcoma; real-time semi-quantitative reverse
transcription-polymerase chain reaction. Cancer Lett 2001, 164:177-188.
24. Sugimachi K, Aishima S, Taguchi K, Tanaka S, Shimada M, Kajiyama K,
Sugimachi K, Tsuneyoshi M: The role of overexpression and gene
amplification of cyclin D1 in intrahepatic cholangiocarcinoma. J Hepatol
2001, 35:74-79.
25. Poser I, Dominguez D, de Herreros AG, Varnai A, Buettner R, Bosserhoff AK:
Loss of E-cadherin expression in melanoma cells involves up-regulation
of the transcriptional repressor Snail. J Biol Chem 2001, 276:24661-24666.
26. Yokoyama K, Kamata N, Hayashi E, Hoteiya T, Ueda N, Fujimoto R,
Nagayama M: Reverse correlation of E-cadherin and snail expression in
oral squamous cell carcinoma cells in vitro. Oral Oncol 2001, 37:65-71.
27. Jiao W, Miyazaki K, Kitajima Y: Inverse correlation between E-cadherin and
Snail expression in hepatocellular carcinoma cell lines in vitro and in
vivo. Br J Cancer 2002, 86:98-101.
28. Lundgren K, Nordenskjöld B, Landberg G: Hypoxia, Snail and incomplete
epithelial-mesenchymal transition in breast cancer. Br J Cancer 2009,
101:1769-81.
29. Yang MH, Chen CL, Chau GY, Chiou SH, Su CW, Chou TY, Peng WL, Wu JC:
Comprehensive analysis of the independent effect of twist and snail in
promoting metastasis of hepatocellular carcinoma. Hepatology 2009,
50:1464-74.
30. Zhang A, Chen G, Meng L, Wang Q, Hu W, Xi L, Gao Q, Wang S, Zhou J,
Xu G, Meng L, Ma D: Antisense-Snail transfer inhibits tumor metastasis
by inducing E-cadherin expression. Anticancer Res 2008, 28:621-8.
31. Berx G, Becker KF, Hofler H, van Roy F: Mutations of the human
E-cadherin (CDH1) gene. Hum Mutat 2008, 12:226-237.
32. Savagner P, Yamada KM, Thiery JP: The zinc-finger protein slug causes
desmosome dissociation, an initial and necessary step for growth factor-
induced epithelial-mesenchymal transition. J Cell Biol 1997,
137:1403-1419.
33. Thiery JP: Epithelial-mesenchymal transitions in tumor progression. Nat
Rev Cancer 2002, 2:442-454.
34. Kanai Y, Ushijima S, Tsuda H, Sakamoto M, Hirohashi S: Aberrant DNA
methylation precedes loss of heterozygosity on chromosome 16 in
chronic hepatitis and liver cirrhosis. Cancer Lett 2000, 148:73-80.
35. Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJ, van de Vijver M,
Cornelisse C, van Roy F: E-Cadherin is a tumour/invasion suppressor gene
mutated in human lobular breast cancers. EMBO J 1995, 14:6107-6115.
36. Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P,
Taite H, Scoular R, Miller A, Reeve AE: E-Cadherin germline mutations in
familial gastric cancer. Nature (Lond.) 1998, 392:402-405.
37. Risinger JI, Berchuck A, Kohler MF, Boyd J: Mutations of the E-cadherin
gene in human gynecologic cancers. Nat Genet 1994, 7:98-102.
38. Doyle S, Evans AJ, Rakha EA, Green AR, Ellis IO: Influence of E-cadherin
expression on the mammographic appearance of invasive nonlobular
breast carcinoma detected at screening. Radiology 2009, 253:51-5.
39. Sarrió D, Palacios J, Hergueta-Redondo M, Gómez-López G, Cano A,
Moreno-Bueno G: Functional characterization of E- and P-cadherin in
invasive breast cancer cells. BMC Cancer 2009, 9:74.
40. Ihara A, Koizumi H, Hashizume R, Uchikoshi T: Expression of epithelial
cadherin and a-a n db-catenins in nontumoral livers and hepatocellular
carcinomas. Hepatology 1996, 23:1441-1447.
41. Wei Y, Van Nhieu JT, Prigent S, Srivatanakul P, Tiollais P, Buendia MA:
Altered expression of E-cadherin in hepatocellular carcinoma:
correlations with genetic alterations, b-catenin expression, and clinical
features. Hepatology 2002, 36:692-701.
42. Endo K, Ueda T, Ueyama J, Ohta T, Terada T: Immunoreactive E-cadherin,
a-catenin, b-catenin, and g-catenin proteins in hepatocellular carcinoma:
relationships with tumor grade, clinicopathologic parameters, and
patients’ survival. Hum Pathol 2000, 31:558-565.
Zhang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:88
http://www.jeccr.com/content/29/1/88
Page 9 of 1043. Hemavathy K, Ashraf SI, Ip YT: Snail/slug family of repressors: slowly going
into the fast lane of development and cancer. Gene (Amst.) 2000,
257:1-12.
44. Thiery JP: Epithelial-mesenchymal transitions in tumor progression. Nat
Rev Cancer 2002, 2:442-454.
45. Barrett K, Leptin M, Settleman J: The Rho GTPase and a putative RhoGEF
mediate a signaling pathway for the cell shape changes in Drosophila
gastrulation. Cell 1991, 91:905-915.
46. Liu JP, Jessell TM: A role for rhoB in the delamination of neural crest cells
from the dorsal neural tube. Development (Camb.) 1998, 125:5055-5067.
doi:10.1186/1756-9966-29-88
Cite this article as: Zhang et al.: The E-cadherin repressor slug and
progression of human extrahepatic hilar cholangiocarcinoma. Journal of
Experimental & Clinical Cancer Research 2010 29:88.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Zhang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:88
http://www.jeccr.com/content/29/1/88
Page 10 of 10